Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead Not Bullet-Proof After All: Harvoni US Sales Tumble More Than 50%

Executive Summary

Incoming President and CEO John Milligan opened Gilead Sciences Inc.'s first quarter earnings call April 28 talking about sales growth of new HIV drugs and pipeline efforts in non-alcoholic steatohepatitis (NASH), but analysts focused in quickly on overall reductions in hepatitis C sales, including a more than 50% decrease year-over-year in US sales of Harvoni.

Advertisement

Related Content

Gilead Sees Prospects For Declining HCV Revenues To Stabilize
When Will Gilead Make Its M&A Move?
Medivir Mulls Separation As Simeprevir Royalties Decline
Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch
Stockwatch: Earnings Move From Mediocre to Worse
AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout
Gilead HCV Sales Decline In US, But Offset By Global Growth

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel